Retatrutide phase 3 data shows sustained metabolic improvements at 68 weeks
Interim results from the TRIUMPH program suggest the triple agonist maintains its lead over dual-incretin therapy on weight and liver-fat endpoints.
ResearchGLP-1 Compounds & Research
The incretin class is the fastest-moving area we cover. Structured compound references, trial tracking, regulatory developments, and independent verification of the gray market — in one hub.
Compound Reference
Semaglutide
GLP-1 receptor agonist
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, supported by large randomized controlled trials.
FDA-approved (branded forms) Tirzepatide
Dual GIP/GLP-1 receptor agonist
A dual-incretin agonist targeting both GIP and GLP-1 receptors, with weight-reduction results exceeding single-agonist therapies in head-to-head trials.
FDA-approved (branded forms) Retatrutide
Triple GIP/GLP-1/glucagon receptor agonist
An investigational triple-agonist in late-stage trials, with phase 2 data showing the largest weight reductions yet reported for an incretin therapy.
Phase 3 clinical trialsGLP-1 Coverage
All research
FDA updates guidance on peptide compounding: what changes and when
The August guidance clarifies bulk-substance eligibility and signals enforcement priorities for the next year.
RegulationNew study explores oral delivery of GLP-1 peptides
Absorption enhancers push oral bioavailability past thresholds previously considered impractical for large peptides.
Research
We Independently Tested 20 Peptide Samples. Here’s What We Found.
Six months, three laboratories, and 20 anonymously purchased samples from 12 companies. Purity ranged from 61% to 99.2% — and two products failed verification entirely.
Special Report